{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:53:55Z","timestamp":1791222835702,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1093\/jac\/dkw011","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T18:14:14Z","timestamp":1455819254000},"page":"1632-1636","source":"Crossref","is-referenced-by-count":26,"title":["Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: Table\u00a01."],"prefix":"10.1093","volume":"71","author":[{"given":"Casper","family":"Rokx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina A. M.","family":"Schurink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A. B.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J. A.","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,2,16]]},"reference":[{"key":"2016051405373504000_71.6.1632.1","unstructured":"Department of Health and Human Services (DHHS). Antiretroviral Guidelines for Adults and Adolescents . Table\u00a06. http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf ."},{"key":"2016051405373504000_71.6.1632.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8722"},{"key":"2016051405373504000_71.6.1632.3","unstructured":"European AIDS Clinical Society (EACS) Guidelines . Page 8. http:\/\/www.eacsociety.org\/files\/2015_eacsguidelines_8.0-english_revised-20151104.pdf ."},{"key":"2016051405373504000_71.6.1632.4","unstructured":"British HIV Association (BHIVA) Guidelines . Table\u00a05.1. http:\/\/www.bhiva.org\/documents\/Guidelines\/Treatment\/2015\/2015-treatment-guidelines.pdf ."},{"key":"2016051405373504000_71.6.1632.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00157-11"},{"key":"2016051405373504000_71.6.1632.6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077448"},{"key":"2016051405373504000_71.6.1632.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-10"},{"key":"2016051405373504000_71.6.1632.8","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283612419"},{"key":"2016051405373504000_71.6.1632.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"2016051405373504000_71.6.1632.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"2016051405373504000_71.6.1632.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"key":"2016051405373504000_71.6.1632.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"2016051405373504000_71.6.1632.13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"2016051405373504000_71.6.1632.14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"2016051405373504000_71.6.1632.15","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2878"},{"key":"2016051405373504000_71.6.1632.16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/QAD.0b013e32835cb997","article-title":"Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002\u20132009","volume":"27","author":"Abgrall","year":"2013","journal-title":"AIDS"},{"key":"2016051405373504000_71.6.1632.17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/QAD.0b013e328354f497","article-title":"The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study","volume":"26","author":"HIV-CAUSAL Collaboration","year":"2012","journal-title":"AIDS"},{"key":"2016051405373504000_71.6.1632.18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-2-201301150-00002"},{"key":"2016051405373504000_71.6.1632.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1590-9"},{"key":"2016051405373504000_71.6.1632.20","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.439"},{"key":"2016051405373504000_71.6.1632.21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f4243b"},{"key":"2016051405373504000_71.6.1632.22","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000407"},{"key":"2016051405373504000_71.6.1632.23","doi-asserted-by":"crossref","first-page":"19525","DOI":"10.7448\/IAS.17.4.19525","article-title":"The PROTEA trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies\/mL","volume":"17","author":"Antinori","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2016051405373504000_71.6.1632.24","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00176-9"},{"key":"2016051405373504000_71.6.1632.25","unstructured":"Figueroa MI , Sued O , Patterson P et al . Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. In: Abstracts of the European AIDS Conference , Barcelona, 2015. Abstract 1066."},{"key":"2016051405373504000_71.6.1632.26","unstructured":"Rojas J , Blanco JL , Lonca M et al . Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression: a 24-week pilot study. In: Abstracts of the European AIDS Conference , Barcelona, 2015. Abstract 1108."},{"key":"2016051405373504000_71.6.1632.27","unstructured":"Katlama C , Souli\u00e9 C , Blanc C et al . Dolutegravir monotherapy in HIV-infected patients with suppressed HIV viremia. In: Abstracts of the European AIDS Conference , Barcelona, 2015. Abstract 714."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/71\/6\/1632\/11282215\/dkw011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T13:31:49Z","timestamp":1654349509000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,16]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,14]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1093\/jac\/dkw011"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw011","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,16]]}}}